Sanyoubio's Guo-Jun Lang: Making Innovative Biologics Accessible to All
Empowering Global Innovative Biologics R&D through Ecosystem Strength
Time：
2026-02-11 20:22
Author：
xieyijun
In Vivo CAR-T: The Race of Money, Technology, and Time
Co-building an Evolvable and Deployable "AI-Driven Automated Laboratory for Biopharmaceuticals"
Time：
2026-02-10 20:15
Author：
xieyijun
Behind the $70 Billion: Merck’s New Narrative
The Year Losing the "King of Drugs": How to Stage a Comeback?
Time：
2026-02-08 19:15
Author：
xieyijun
IIT Behind China’s “Fast Track”: Misread and Scrutinized
From "China’s Path" to "Global Agenda"
Time：
2026-02-07 18:39
Author：
xieyijun
The ceiling for small nucleic acid drugs is being lifted.
The First Blockbuster Small Nucleic Acid Drug Is Born
Time：
2026-02-07 18:48
Author：
xieyijun
Eli Lilly: The Crowning of a "New King"
Undertows and Smoke of the Battlefield in Weight-Loss Drugs
Time：
2026-02-05 18:28
Author：
xieyijun
When ADC Giants Hit the Brakes
Daiichi Sankyo Terminates DS-9606
Time：
2026-02-05 08:23
Author：
xieyijun
FDA Approval Quest: The Crossroads for PD-(L)1/VEGF Bispecific Antibodies
A countdown of less than 10 months
Time：
2026-02-04 09:20
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务